万基遗传2026年关注点：业绩预期、AI商业化与行业竞争

Group 1: Financial Performance - The company raised its full-year revenue guidance for 2025 to $325 million, representing a 15% year-over-year growth, and the market will focus on whether the actual performance meets or exceeds this expectation [1] Group 2: Business Development - The company is emphasizing investments in AI and digital pathology to enhance laboratory service efficiency and advance its therapeutic development pipeline. In 2026, attention will be on the commercialization progress of AI technology in genetic testing and clinical breakthroughs in its therapeutic pipeline, particularly in oncology [2] Group 3: Industry Policy and Environment - The FDA approval process is becoming more standardized in 2026, and competition in the precision medicine field, particularly at the intersection of gene editing and AI, is intensifying. The company needs to maintain its innovative edge amid technological advancements in the sequencing domain [3]